Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 6Lung Neoplasms 5Breast Neoplasms 5Prostatic Neoplasms 3Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma 2Gastrointestinal Neoplasms 2Uterine Cervical Neoplasms 1Support of the Family as a Caregiving System 1Stomach Neoplasms 1Sarcoma 1Quality of Life 1Pseudomyxoma Peritonei 1Paranasal Sinus Neoplasms 1Papillomavirus Infections 1Pain 1Ovarian Neoplasms 1Otorhinolaryngologic Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Mixed Dementias 1Mesothelioma, Malignant 1Meningeal Carcinomatosis 1Maxillary Sinus Neoplasms 1Malignant Female Reproductive System Neoplasm 1Lymphoma, Follicular 1

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Referral and Consultation × Clear all
NCT06908629 2025-08-26

Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors

Barbara Ann Karmanos Cancer Institute

Phase NA Recruiting
120 enrolled
EndocrineGastrointestinalNETPlasma cell

Gastrointestinal Neoplasms, Multiple Myeloma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡